HealthNotableReported
5.2
Sanofi pays $1B to Regeneron for Dupixent successor antibodies
Le SoirLO·FR · US·about 15 hours ago
Sanofi and Regeneron have closed an expansion of their immunology co-development and marketing alliance, with a potential value of up to $8 billion for Regeneron. The deal deepens an existing partnership, signaling continued investment in immunology pipelines. Financial terms and specific programs remain undisclosed, limiting immediate market impact assessment.